RLMD (Relmada Corp) יחס שווי שוק לשווי בספרים

Relmada Therapeutics (RLMD) maintains a strong reputation among psychiatrists, although global conflicts complicate patent protection and component supplies. This price trend chart illustrates the stock dynamics of the depression treatment developer, where the indicator stands at 1.65. The business potential relies on high margins: creating a single successful molecule allows the company to capture a colossal global market with minimal costs.

Investors must filter out speculative risks by assessing the real value of Relmada Therapeutics (RLMD) assets. The absence of sales and linear growth in late-stage testing costs leave the company dependent on capital. Analyzing the ratio of market capitalization to book value reveals a market premium over net assets. The current value of 1.65 indicates the degree of price overheating relative to the balance sheet. A wide gap reduces the margin of safety during stress scenarios.